Radioimmunotherapy of patients with small-volume tumors using iodine- 131-labeled anti-CEA monoclonal antibody NP-4 F(ab')2

Journal of Nuclear Medicine

Volumn 37, Issue 9, 1996, Pages 1504-1510

  Juweid, Malik E ^a   Sharkey, Robert M ^a   Behr, Thomas ^a   Swayne, Lawrence C ^a   Dunn, Robert ^a   Siegel, Jeffry ^a   Goldenberg, David M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

carcinoembryonic antigen; monoclonal antibodies; radioimmunotherapy; small volume disease

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN F(AB')2 FRAGMENT; MONOCLONAL ANTIBODY I 131; MONOCLONAL ANTIBODY NP4 I 131; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; DRUG CLEARANCE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; THYROID MEDULLARY CARCINOMA; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEASIBILITY STUDIES; FEMALE; HUMANS; IODINE RADIOISOTOPES; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE;

EID: 0029779766     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Vriesendorp HM, Hepst JM, Germack MA, et al. Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including radiation therapy oncology group 87-01. J Clin Oncol 1991;9:918-928.
2. 131I Lym-1 monoclonal antibody. Antibod Immunoconj Radiopharm 1988;1:17-33.
3. Goldenberg DM, Horowitz JA, Sharkey RM, et al. Targeting, dosimetry and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol 1991;9:548-564.
4. Juweid M, Sharkey RM, Markowitz A, et al. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res 1995;55:5899s-5907s.
5. 131I]anti-B1 (anti-CD20) antibody. N Engl J Med 1993;329:459-465.
6. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219-1224.
7. 131I monoclonal antibody 17-1A treatment to external beam radiation on the growth of LS174T human colon carcinoma xenografts. Int J Radiat Oncol Biol Phys 1990;18:1033-1041.
8. 90Y-lymphoma therapy. Cancer 1994;73:966-973.
9. Epenetos AA, Munro AJ, Stewart S, et al. Antibody-guided mediation of advanced ovarian cancer with intrapentoneally administered radiolabeled monoclonal antibodies. J Clin Oncol 1987;5:1890-1899.
10. 131I labeled monoclonal antibodies. Int J Radiat Oncol Biol Phys 1989;16:405-413.
11. 131I-COL-1 in patients with advanced gastrointestinal (Gl) malignancies [Abstract]. Antibod immunoconj Radiopharm 1992;5:344.
12. 131I-labeled monoclonal antibody CC49 in colorectal cancer [Abstract]. Eur J Nucl Med 1992;19: 709.
13. 131I-CC49. Cancer 1994;73(suppl):1057-1066.
14. 131I-conjugated monoclonal antibody CC49: a Phase I trial [Abstract]. Antibody Immunoconj Radiopharm 1993;6:90.
15. Maxon HR, Thomas SR, Hertzberg VS, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983;309:937-941.
16. Larson SM, Leibel SA, Cheung NKV. Radioisotope conjugates. In: Biologic therapy of cancer. DeVita VT Jr, Hellman S, Rosenberg SA, eds. J.B. Lippincott, Philadelphia 1991;496-511.
17. Goldenberg DM. Monoclonal antibodies in cancer detection therapy. Am J Med 1993;94:297-312.
18. 131I-labeled anticarcinoembryonic antigen monoclonal antibody. Cancer Res 1990;50: 1039s-1042s.
19. Sharkey RM, Primus FJ, Goldenberg DM. Antibody protein dose and radioimmunodetection of GW-39 human colon tumor senografts. Int J Cancer 1987;39:611-617.
20. Blumenthal RD, Sharkey RM, Kashi R, Natale AM, Goldenberg DM. Influence of animal host and tumor implantation site on radioantibody uptake in the GW-39 human colonie cancer xenograft. Int J Cancer 1989;44:1041-1047.
21. Hagan PI, Halpern SE, Dillman RO, et al. Tumor size: effect on monoclonal antibody uptake in tumor models. J Nucl Med 1986;27:422-427.
22. Moshakis V, Mcilhinney RAJ, Raghaven D, Neville AM. Localization of human tumor xenografts after intravenous administration of radiolabeled monoclonal antibodies. Br J Cancer 1981;44:91-99.
23. Primus FJ, Newell KD, Blue A, Goldenberg DM. Immunological heterogeneity of carcinoembryonic antigen: antigenic determinants on carcinoembryonic antigen distinguished by monoclonal antibodies. Cancer Res 1983;43:686-692.
24. Weadock KS, Sharkey RM, Varga DC, Goldenberg DM. Evaluation of a remote radioiodination system for radioimmunotherapy. J Nucl Med 1990;31:508-511.
25. Horowitz JA, Goldenberg DM, DeJager R, et al. Phase I-II trial of radioimmunotherapy (RAIT) with I-131-labeled anti-CEA and anti-APP monoclonal antibodies (MAbs) [Abstract]. J Nucl Med 1988;29:846.
26. Primus FJ, Kelley EA, Hansen HJ, Goldenberg DM. "Sandwich"-type immunoassay for carcinoembryonic antigen in patients receiving murine monoclonal antibodies for diagnosis and therapy. Clin Chem 1988;34:261-264.
27. Loevinger R, Berman M. A revised scheme for calculating the absorbed dose from biologically distributed radionuclide MIRD Pamphlet No. 1, revised. New York: Society of Nuclear Medicine, 1976.
28. Bigler R, Zanzonico PB, Leonard R, et al. Bone marrow dosimetry for monoclonal antibody therapy. In: Proceedings of the fourth international radiopharmaceutical dosimetry symposium. Oak Ridge Associated Universities, Oak Ridge, TN 1986;535-544.
29. Cloutier RV, Watson EE, Rohrer RH, et al. Calculating the radiation dose to an organ. J Nucl Med 1973;14:53-55.
30. 2 in patients with advanced colorectal carcinoma. Antibody Immunoconj Radiopharm 1993;6:239-255.
31. Chatal JF, Saccavini JC, Thedres P, et al. Biodistribution of indium-111-labeled OC 125 monoclonal antibody intraperitoneally injected into patients with ovarian cancer. Cancer Res 1989;49:3087-3094.
32. Sharkey RM, Juweid M, Shevitz J, et al. Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen (CEA) monoclonal antibody in preclinical and clinical studies. Cancer Res 1995;55:5935s-5945s.